Dapagliflozin Evaluation on Atrial Fibrillation Patients Followed Cox Maze IV Procedure

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 348 participants.

Also called NCT05816733

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 348 participants (planned count) (from the registry)
Sponsor
Kun Hua (from the registry)
Registry
  • NCT NCT05816733
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05816733. Randomized; double masking; primary purpose prevention. Start 2023-09-01 (actual); primary completion 2024-06-07 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Dapagliflozin Evaluation on Atrial Fibrillation Patients Followed Cox Maze IV Procedure
Acronym
DETAIL-CMIV
Condition
Atrial Fibrillation Recurrence
Condition
Cox Maze IV
Condition
Patients With or Without Heart Failure and Diabetes
Intervention (Drug)
Dapagliflozin
Intervention (Drug)
Placebo
Lead sponsor
Kun Hua (class: other)

Record details

Record id
cardio:ct-nct05816733
Content hash
844cb087c72fa6c30aacd5bffbfb80ac60e72cce59bd1f0f9a03bc21ead6ea6f